AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A compound comprising an oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising an at least 8 consecutive nucleobase portion of SEQ ID NO: 64, wherein said nucleobase sequence of said oligonucleotide is 100% complementary to SEQ ID NO:17 as measured over the entirety of said oligonucleotide.

2. (Previously Presented) The compound of claim 1, wherein said oligonucleotide is an antisense oligonucleotide.

3. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

4. (Original) The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

5. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

6. (Previously Presented) The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety or a 4'- $(CH_2)_n$-O-2' bridge, wherein n is 1 or 2.

7. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

8. (Original) The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

9. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

10. (Canceled).

11. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

12. (Original) The composition of claim 11 further comprising a colloidal dispersion system.

13. (Previously Presented) The composition of claim 11 wherein the oligonucleotide is an antisense oligonucleotide.

14. (Previously Presented) A method of inhibiting the expression of BCL2-associated X protein in cells or tissues in vitro comprising contacting said cells or tissues with the compound of claim 1 such that expression of BCL2-associated X protein is inhibited.

15. (Previously Presented) The compound of claim 1 wherein the compound comprises ISIS 134323.

16. (Previously Presented) The compound of claim 1 wherein the compound consists of SEQ ID NO: 64.

17. (Previously Presented) The compound of claim 2 wherein the oligonucleotide comprises:

a gap segment consisting of linked deoxynucleotides;

a 5' wing segment consisting of linked nucleotides;

a 3' wing segment consisting of linked nucleotides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleotide of each wing segment comprises a modified sugar.

18. (Currently Amended) The compound of claim 17 wherein the oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleotides;

a 5' wing segment consisting of five linked nucleotides;

a 3' wing segment consisting of five linked nucleotides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleotide of each wing segment comprises a 2'-O-methoxyethyl sugar, wherein each cytosine in said oligonucleotide is a 5-methylcytosine and wherein each internucleoside linkage in said oligonucleotide is a phosphorothioate linkage.

19. (Previously Presented) The compound of claim 18, wherein said oligonucleotide is 20 nucleobases in length and consists of SEQ ID NO:64.

20. (New) A compound comprising an oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence comprising an at least 8 consecutive nucleobase portion of nucleobases 263-326 of SEQ ID NO:17, wherein said nucleobase sequence of said

oligonucleotide is 100% complementary to SEQ ID NO:17 as measured over the entirety of said oligonucleotide.

21. (New) The compound of claim 20, consisting of a single-stranded modified oligonucleotide.

22. (New) The compound of claim 21, wherein at least one internucleoside linkage is a modified internucleoside linkage.

23. (New) The compound of claim 22, wherein each internucleoside linkage is a phosphorothioate internucleoside linkage.

24. (New) The compound of claim 21, wherein at least one nucleoside comprises a modified sugar.

25. (New) The compound of claim 24, wherein at least one modified sugar is a bicyclic sugar.

26. (New) The compound of claim 24, wherein at least one modified sugar comprises a 2'-O-methoxyethyl or a 4'- $(CH_2)_n$-O-2' bridge, wherein n is 1 or 2.

27. (New) The compound of claim 21, wherein at least one nucleoside comprises a modified nucleobase.

28. (New) The compound of claim 27, wherein the modified nucleobase is a 5-methylcytosine.

29. (New) The compound of claim 20, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;

a 5' wing segment consisting of linked nucleosides;

a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

30. (New) The compound of claim 29, wherein the modified oligonucleotide comprises:

a gap segment consisting of ten linked deoxynucleosides;

a 5' wing segment consisting of five linked nucleosides;

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; wherein each cytosine in said modified oligonucleotide is a 5-methylcytosine, and wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage.

31. (New) The compound of claim 30, wherein the modified oligonucleotide consists of 20 linked nucleosides.

32. (New) A composition comprising the compound of claim 20 or a salt thereof and a pharmaceutically acceptable carrier or diluent.

33. (New) The composition of claim 32, wherein said modified oligonucleotide consists of a single-stranded oligonucleotide.

34. (New) The composition of claim 32, wherein the modified oligonucleotide consists of 20 linked nucleosides.

35. (New) The compound of claim 20 wherein the compound comprises a chimeric oligonucleotide compound selected from the group consisting of ISIS 134318 to ISIS 134324.

36. (New) The compound of claim 20 wherein the compound comprises a nucleobase sequence selected from the group consisting of SEQ ID NOs: 59-65.

37. (New) The compound of claim 20 wherein the compound consists of a nucleobase sequence selected from the group consisting of SEQ ID NOs: 59-65.

38. (New) A method of inhibiting the expression of BCL2-associated X protein in cells or tissues in vitro comprising contacting said cells or tissues with the compound of claim 20 such that expression of BCL2-associated X protein is inhibited.